Contrast Agent Administration
Contrast Agent Administration - Related Videos
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
07:15
In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
0 Views •
Cited by 2 •
2013
We demonstrate how to perform macrophage MR imaging using ultrasmall superparamagnetic contrast agent (USPIO) in septic arthritis, allowing an initial and longitudinal in vivo non-invasive evaluation of macrophages infiltration and an assessment of therapy efficacy.
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
0 Views •
Cited by 3 •
2013
To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer model.
13:21
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 9 •
2011
We demonstrate the metalation, purification, and characterization of lanthanide complexes. The complexes described here can be conjugated to macromolecules to enable tracking of these molecules using magnetic resonance imaging.
09:38
Compound Administration II
0 Views •
2016
Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN Compound administration is often an integral component of an animal study. Many factors need to be evaluated to ensure that the compound is delivered correctly. The route of administration affects the mechanisms of absorption. The characteristics of the substance to be introduced (the pH, viscosity, and concentration) may dictate which route of administration is selected.
FAQs
The imaging modality determines how an agent creates contrast. In MRI, the agent changes local magnetic relaxation, whereas in CT it changes X-ray attenuation. This distinction affects which tissues or vascular features become more conspicuous and how researchers interpret enhancement. Consequently, contrast-agent selection must match the scanner modality and the neuroanatomical or pathological feature under investigation.
Distribution and timing influence which biological processes appear on the scan. Their patterns can provide information about vascular perfusion, blood-brain barrier disruption, inflammation, or tumor-associated changes. Enhancement therefore reflects more than simple anatomical visibility: researchers evaluate when and where the agent appears to distinguish vascular and pathological features, supporting more informative interpretation of brain images.
Agent selection, dose, imaging sequence, and monitoring all influence the usefulness of contrast-enhanced images. The chosen combination affects how clearly structures or abnormalities are represented and helps limit risk during administration. Controlling these variables is especially important when comparing findings across scans, because differences in technique can affect both image interpretation and assessment of pathological change.
A typical workflow involves selecting an appropriate imaging agent, delivering it intravenously before MRI or CT, and coordinating image acquisition with the planned sequence. Monitoring accompanies the administration so that the procedure remains controlled and risks are limited. The resulting images are then interpreted in relation to agent distribution, timing, and the neurological feature being examined.
Researchers use this approach when enhanced visualization is needed for neuroanatomical mapping, disease characterization, treatment planning, or evaluation of therapeutic response. It can make brain structures, blood vessels, lesions, and pathological changes more conspicuous than they may be on non-enhanced images. These applications connect imaging findings with both anatomical organization and disease-related alterations in the nervous system.
Contrast-enhanced images can help characterize changes associated with perfusion, blood-brain barrier disruption, inflammation, and tumors. They may also show how disease-related features relate to surrounding brain anatomy, which supports treatment planning and follow-up. In research and clinical assessment, comparing these findings over time can help evaluate whether a therapeutic response is occurring.